These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 1369122)

  • 81. Advances in understanding the pharmacological properties of antisense oligonucleotides.
    Crooke ST
    Adv Pharmacol; 1997; 40():1-49. PubMed ID: 9217922
    [No Abstract]   [Full Text] [Related]  

  • 82. Regulatory concerns for the chemistry, manufacturing, and controls of oligonucleotide therapeutics for use in clinical studies.
    Kambhampati RV; Chiu YY; Chen CW; Blumenstein JJ
    Antisense Res Dev; 1993; 3(4):405-10. PubMed ID: 8155982
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Bioanalysis considerations on the pharmacokinetic evaluation of antisense therapeutics.
    Norris DA; Post N; Yu RZ; Greenlee S; Wang Y
    Bioanalysis; 2019 Nov; 11(21):1909-1912. PubMed ID: 31648523
    [No Abstract]   [Full Text] [Related]  

  • 84. Commentary: regulatory issues affecting oligonucleotides.
    Crooke ST
    Antisense Res Dev; 1993; 3(3):301-6. PubMed ID: 8286931
    [No Abstract]   [Full Text] [Related]  

  • 85. Prospects for gene-directed therapy with antisense oligodeoxynucleotides.
    Calabretta B; Skorski T; Szczylik C; Zon G
    Cancer Treat Rev; 1993 Apr; 19(2):169-79. PubMed ID: 8481928
    [No Abstract]   [Full Text] [Related]  

  • 86. Oligonucleotide therapeutics: coming 'round the clubhouse turn.
    Hawkins JW
    Antisense Res Dev; 1995; 5(1):1. PubMed ID: 7613070
    [No Abstract]   [Full Text] [Related]  

  • 87. Oligonucleotide therapeutics: a prospectus.
    Crooke S
    Antisense Res Dev; 1993; 3(1):1-2. PubMed ID: 8495103
    [No Abstract]   [Full Text] [Related]  

  • 88. Synthesis, physicochemical and biological properties of oligonucleotides incorporated with amino-isonucleosides.
    Wang F; Chen Y; Huang Y; Jin HW; Zhang LR; Yang ZJ; Zhang LH
    Sci China Chem; 2012; 55(1):70-79. PubMed ID: 32214999
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Antisense oligonucleotide-based therapeutics for cancer.
    Dean NM; Bennett CF
    Oncogene; 2003 Dec; 22(56):9087-96. PubMed ID: 14663487
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Antisense technology.
    Crooke ST
    Curr Opin Biotechnol; 1991 Apr; 2(2):282-7. PubMed ID: 1367866
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Progress toward oligonucleotide therapeutics: pharmacodynamic properties.
    Crooke ST
    FASEB J; 1993 Apr; 7(6):533-9. PubMed ID: 7682523
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Oligonucleotide therapy.
    Crooke ST
    Curr Opin Biotechnol; 1992 Dec; 3(6):656-61. PubMed ID: 1369122
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Progress in antisense oligonucleotide therapeutics.
    Crooke ST; Bennett CF
    Annu Rev Pharmacol Toxicol; 1996; 36():107-29. PubMed ID: 8725384
    [TBL] [Abstract][Full Text] [Related]  

  • 94.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 95.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 96.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 97.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 98.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 99.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 100.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.